Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
✨ Onyx AI Summary Belite Bio completed the last patient visit in DRAGON, its pivotal Phase 3 trial of oral tinlarebant in adolescents with Stargardt disease type 1 (104 enrolled across 11 regions; primary endpoint is growth rate of atrophic lesions), with topline results slated for Q4 2025. Tinlarebant aims to